Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.

Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Auñón P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, Pérez-Moreno PD, López-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA, coopERA Breast Cancer study group

Open source

DOI: 10.1016/s1470-2045(23)00268-1
Published: 2023 Sep
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-23-00268-1,
  title = {Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.},
  author = {Hurvitz SA and Bardia A and Quiroga V and Park YH and Blancas I and Alonso-Romero JL and Vasiliev A and Adamchuk H and Salgado M and Yardley DA and Berzoy O and Zamora-Auñón P and Chan D and Spera G and Xue C and Ferreira E and Badovinac Crnjevic T and Pérez-Moreno PD and López-Valverde V and Steinseifer J and Fernando TM and Moore HM and Fasching PA and coopERA Breast Cancer study group},
  year = {2023},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(23)00268-1},
  url = {https://doi.org/10.1016/s1470-2045(23)00268-1}
}

RIS

TY  - JOUR
TI  - Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
AU  - Hurvitz SA
AU  - Bardia A
AU  - Quiroga V
AU  - Park YH
AU  - Blancas I
AU  - Alonso-Romero JL
AU  - Vasiliev A
AU  - Adamchuk H
AU  - Salgado M
AU  - Yardley DA
AU  - Berzoy O
AU  - Zamora-Auñón P
AU  - Chan D
AU  - Spera G
AU  - Xue C
AU  - Ferreira E
AU  - Badovinac Crnjevic T
AU  - Pérez-Moreno PD
AU  - López-Valverde V
AU  - Steinseifer J
AU  - Fernando TM
AU  - Moore HM
AU  - Fasching PA
AU  - coopERA Breast Cancer study group
PY  - 2023
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(23)00268-1
UR  - https://doi.org/10.1016/s1470-2045(23)00268-1
ER  -

APA

SA, H., A, B., V, Q., YH, P., I, B., JL, A., A, V., H, A., M, S., DA, Y., O, B., P, Z., D, C., G, S., C, X., E, F., T, B. C., PD, P., V, L., J, S., TM, F., HM, M., PA, F., & group, C. B. C. S. (2023). Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(23)00268-1

Source records

pubmed · retrieved 2026-09-27T07:07:02.379Z